Document:

Exhibit 10.1

MANUFACTURING AND SALES LICENSE AGREEMENT

 

This Manufacturing and Sales License Agreement (this
“Agreement”) is entered into and made effective as of October 31, 2022 (the “Effective Date”), by
and between Aphria, Inc., an Ontario corporation (the “Company”) with a registered office at 98 Talbot St. W., Leamington,
ON N8H 1M8, and Charlotte’s Web, Inc., a Delaware, USA corporation
headquartered at 700 Tech Ct., Louisville, CO 80027 (“CW”). Each of the Company and CW are referred to herein as a
“Party” and collectively as the “Parties.”

 

RECITALS:

 

		1.	CW markets and sells certain products, based upon proprietary and in some cases patented hemp cultivars,
including cannabidiol, other cannabinoids, and other substances derived from the hemp plant (“Hemp Extract”) in the
United States and elsewhere. CW has registered its proprietary hemp cultivars in Canada but is not a licensed producer of cannabis or
Hemp Extract products in Canada.

 

		2.	The Company is a licensed producer of medical and adult-use cannabis products in Canada.

 

		3.	CW has contracted with a Canadian hemp grower, HyTech Production, Inc. (“Cultivator”),
to cultivate Biomass (defined below) from CW’s proprietary cultivars. CW’s Cultivator is registered with and licensed by Canadian
government agencies as required by law.

 

		4.	CW and the Company intend that the Company will obtain delivery of the Biomass from Cultivator and then
manufacture same into the hemp-based Products (defined below), and then sell the Products to provincial government-licensed distributors
of cannabis and Hemp Extract products, with the Company paying CW a royalty on all such sales.

 

NOW, THEREFORE, in consideration of the following
promises and for other and further consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, desiring
to be legally bound, do hereby covenant and agree as follows.

 

		1.	Definitions. In addition to the various defined terms set forth elsewhere in this Agreement,
the following terms each shall have the meaning set forth below:

 

		(a)	“Affiliate” shall mean one legal person who owns a majority of the voting stock of,
or controls, is controlled by, or is under common control of, another legal person.

 

		(b)	“Biomass” shall mean hemp raw material cultivated from CW proprietary hemp cultivars
harvested and processed and meeting Health Canada specifications intended to create the Products.

 

		(c)	“Contract Year” shall mean any full calendar year during the Term, starting from the
Effective Date, as well as a partial calendar year at the beginning and/or end of the Term.

 

		(d)	“Dollar” shall mean the Canadian Dollar unless otherwise specified.

 

		(e)	“Net Sales” shall mean the net sales revenues derived by the Company from its sales
of Products less discounts, fees, returns, promotions, and applicable taxes (including for clarity excise taxes imposed by the Canada
Revenue Agency and regulatory fees imposed by Health Canada).

    Page 1 of 13

     

    

 

 

 

		(f)	“Products” shall mean those particular CW products which hereafter may be listed on
Exhibit A hereto, as may be amended from time to time, and as such Products may be regulated under the Cannabis Act (S.C.
2018, c. 16) or other applicable legislation and destined for sale in the Territory.

1313

		(g)	“Territory” shall mean Canada.

 

		2.	License to Manufacture and Sell Products; Pricing; Forecast. 

 a) Subject to the terms and
conditions set out herein, including the grant of license by CW to Company in Section 7, CW hereby grants to the Company a non-transferable,
non-sublicensable, exclusive license to (i) extract Hemp Extract from the biomass received from the Cultivator for the sole purpose of
manufacturing Products within the Territory during the Term, and (ii) manufacture, market, distribute and sell the Products within the
Territory during the Term. The Products, which are those which are listed on Exhibit A, may be expanded, or contracted, or otherwise
amended, only by mutual written agreement of the Parties from time to time. However, any discontinued product may be deleted unilaterally
by CW at any time upon thirty (30) days’ notice to the Company.

b) Company shall have sole discretion
to set and adjust the pricing of Products during the Term. Company commits to pricing the Products at or above the mean price per mg
CBD in the market as the standard price but shall have discretion to implement discounts and promotions as commercially reasonable.

c) Company shall, on the Effective
Date and on a quarterly basis thereafter, submit a six-month rolling forecast (the “Forecast”) to CW that includes
Company’s good faith estimate of the amount of Products to be produced, including any changes to Specifications permitted or contemplated
in accordance with this Agreement, by Company for sale by Company across the Territory during such period.

		3.	Right to New Product Introduction into the Territory. If at any time CW decides to introduce
a new CW cannabis or hemp-based product not then listed on Exhibit A (a “New Product”) into the Territory, the
Company will have the exclusive right, to be exercised by Company within thirty (30) days of being given notice (or otherwise being made
aware) of the proposed introduction, to bring the New Product into the Territory during the Term of the Agreement. In the event the Company
exercises its right in this Section 3, the Parties shall promptly amend Exhibit A of the Agreement to include such New Products(s) as
a Product. If the Company does not exercise its right to launch the New Product, CW may seek an alternative partner in the Territory to
launch its desired New Product.

		4.	Exclusivity. The Company shall have the exclusive right to sell and distribute the Products
in all channels, including medical, adult-use, and pharmacy (when permissible) where the Products may be legally sold and distributed
in the Territory during the Term. Such exclusivity shall extend to New Products only when and if they are added to Exhibit A in
accordance with Section 3 above. Except for CW servicing clients that possess a Health Canada Exemption Letter as provided under subsection
140(1) of the Cannabis Act (CA), The Parties further agree and acknowledge that they intend for this provision to survive the earlier
expiry or termination of this Agreement until October 31, 2026 if the Agreement is terminated by CW for convenience or by Company for
breach pursuant to Section 13. Company shall act as the sole and exclusive channel for the sale of the Products in the Territory; provided,
however, in the event of change of applicable laws to allow direct to consumer or broader retail sales (pharmacy sales channel), the Company’s
exclusivity would apply only to brick and mortar sales, while Company and CW would both be permitted to engage in direct to consumer ecommerce
sales in pharmacy sales channel throughout Territory. The exclusive rights granted to Company are subject to Company meeting the minimum
sales goals as provided for in Section 10(b).

    Page 2 of 13

     

    

 

 

 

		5.	Biomass Acquisition. Company shall acquire all Biomass needed to produce the Products by
entering into a purchase agreement with Cultivator in a form acceptable to Company setting forth all contractual and legal requirements
necessary for Company to purchase such Biomass from Cultivator.

		6.	Manufacturing Process and Requirements.

 (a)       Separation.
Company agrees to respect the confidentiality of the recipes, formulas and processes used to manufacture the Products, and to take all
possible and necessary measures to protect this information and restrict access to such information to limited and specific employees,
consultants, advisors, competitors, and prospective customers on a need-to-know basis.

 (b)       Manufacturing
Standards & Procedures. Company shall adopt and maintain quality assurance procedures, perform periodic quality control tests,
conduct audits and implement measures to ensure that all of the Products manufactured hereunder conform to applicable (as defined below),
“Good Production Practices Guidelines” promulgated by Health Canada, any other standards, protocols, audits or tests reasonably
requested by CW, its customers or distributors, the applicable Specifications (as defined below) and other applicable requirements of
any governmental authority (collectively the “QA Procedures”). In the licensed Territory the Company will follow Health
Canada’s Cannabis Act Regulations. CW will audit to ensure the quality standards are followed under Health Canada and its requirements.
Company agrees to use industry best practices to regularly monitor and maintain (i) the quality of raw materials, and (ii) the quality
and sanitary condition of all equipment used to store, handle, process, manufacture, package and deliver the Products. Company will ensure
that it has qualified staff that can oversee quality and sanitary conditions of its factory, as well as professional staff that can ensure
the quality of raw materials. At the request of CW, Company shall promptly submit to CW in writing a description of its QA Procedures
and shall adopt and incorporate in the Specifications such additional quality control procedures (which shall be included in the definition
of (“QA Procedures”) as CW may require, pending prior approval and alignment with Company. If any direct conflict
in QA Procedures is found between this Agreement and the separate Quality Agreement entered by both Parties, the Quality Agreement procedures
will prevail. Representatives of CW may (but shall not be obligated to), during normal business hours and upon at least forty-eight (48)
hours prior notice to Company, visit and inspect Company’s facilities to view production, audit waste, collaborate on best practices
and/or perform such quality control testing according to established and agreed upon specifications, methods, and labs, of the Products
as CW determines to be reasonably necessary or desirable to ensure Company’s compliance with the provisions of this Agreement.
Company represents and warrants that its manufacturing facilities are (and during the term of this Agreement will be) registered with
all required government agencies and in compliance with all applicable regulations and standards. For purposes of this Agreement, “GPPs”
means current good production practices, applicable guidance documents issued by Health Canada and similar requirements of other countries
to the extent that they are relevant (as applicable).

(c)       Sourcing
of Raw Materials and Packaging. Company agrees it will only use raw materials and packaging materials (“Materials”)
sourced pursuant to the Specifications (as defined herein) for the manufacture of Product and approved for use in the facility by the
Company. The Parties acknowledge that for Company to satisfy its obligations under this Agreement, Company shall purchase Materials and
make certain other expenditures in connection with the manufacture of the Products. Thus, Company shall procure the Materials based upon
the applicable demand for the Products. Company is responsible for procuring all Materials from suppliers approved by CW and ensuring
the quality of the components through supplier-provided Certificate of Analysis compliance and in accordance with Company’s internal
procedures for supplier and material approval; provided, that (i) all suppliers of Materials shall be designated by CW or otherwise approved
by CW in writing prior to use; (ii) Company and CW will work together closely to source Materials and share best practices to maximize
efficiencies; (iii) CW has the right to review Company’s quality control procedures, observe production and collaborate on best
practices; and (iv) Company shall employ commercially reasonable efforts to control costs associated with the purchase of Materials.

    Page 3 of 13

     

    

 

 

7.       Packaging,
Labels and Marketing Materials. Company shall be solely responsible for ensuring that all packaging, labeling and marketing materials
relating to the Products are in compliance with any applicable federal or provincial laws and regulations. CW hereby grants to the Company
a limited, royalty-free, non-transferable, exclusive license during the Term of this Agreement to use CW’s tradenames, trademarks
and logos hereto (the “CW Trademarks”), solely in the Territory for the purposes of producing and distributing the
packaging, labeling, and marketing materials for the Products in accordance with this Agreement. The Company undertakes to appropriately
mark the Products and the marketing material to identify CW as the owner of such CW Trademarks, in a manner that is clear and evident
to third parties, and mention that the use of the CW Trademarks is under license by the Company. All Product packaging, labels, and marketing
materials, used by the Company with respect to the Products or including the CW Trademarks shall be preapproved in writing by CW and approved
by the Company for use in Canada according to the Health Canada’s Cannabis Regulations and Packaging and labelling guide for cannabis
products.

		8.	Quality Standards; Testing of Products. 

(a) Specifications.
Company shall manufacture the Products in accordance with the Product specifications (the “Specifications”) set forth
in the Quality Agreement attached hereto as Exhibit B. CW may amend the Specifications at any time. The Parties shall mutually
agree on the allocation of expenses and costs required to implement any proposed changes to Specifications and pricing amendments prior
to the effectiveness of the proposed amendment. Company shall then implement such amendment in a mutually agreed upon time frame. CW’s
Quality Control and New Product Development departments shall create and send to the Company specific criteria to be incorporated into
the Specifications for the New Product, including (a) the specifications of the Hemp Extract to be used in the New Product; (b) the specifications
of such New Product itself; and (c) the quality release specifications for such New Product. Company shall not make any change or alteration
in the Specifications or the design or manufacture of any Products (or any part or component thereof) (“Change”) without
CW’s prior written consent. If a Change is required in order to correct a defect in, or a nonconformity to, the Specifications of
any Product (whether such defect or nonconformity is discovered by CW or Company), then Company shall make such Change and shall bear
any design, engineering, materials, or manufacturing costs incurred in making such Change.

		(b)	Testing and Inspection. The Company shall permit CW or its agent, at CW’s expense,
to conduct periodic tests of the quality of the Products manufactured by the Company, within a reasonable timeframe from the point of
manufacture, in accordance with the Cannabis Regulations, and with the Specifications, and to verify that they continue to meet the Specifications
and are in compliance with any applicable laws or regulations, as well as periodic inspections of the Company’s extraction and manufacturing
facilities.

		(c)	Compliance with Laws; Recalls. It shall be the Company’s responsibility to comply
with all applicable federal, provincial and other laws and regulations involved in the Company’s carrying out its extraction, manufacturing,
marketing, distribution, sales and other duties as provided herein. The Company shall report to CW, within five (5) days of receipt thereof,
any notice or demand for a Product recall in the Territory. However, the handling of such recall shall be solely the responsibility of
the Company, at its sole cost and expense, and the Company shall fully indemnify CW and save CW harmless from any cost, expense or liability
(including, without limitation, legal fees) incurred by CW as a consequence of any breach or alleged breach by the Company of any such
laws or regulations, or as a consequence of any such recall demand.

    Page 4 of 13

     

    

 

 

		9.	Permitted Use of Third-Party Distributor.

Company within its sole discretion
may appoint one or more entities to transport distribute, promote, market and sell the Products in the Territory (“Distributor”).
Distributor shall not market, sell or distribute Products outside of the Territory.

		10.	Marketing Budgets and Expenditures; Minimum Sales Goals.

		(a)	Minimum Marketing and Sales Spending. Company agrees to spend, in each Contract Year (other
than 2022) a minimum of five percent (5%) of Net Sales per year on advertising, retail marketing, direct to consumer advertising, and
similar third-party marketing expenditures for the Products. In addition, the Company agrees to spend an additional $250,000 (Canadian
dollars) on marketing in the first Contract Year following 2022 to launch the CW brand into the Canadian market. Failure to spend this
amount in any such Contract Year shall be deemed a material breach of this Agreement. All marketing and promotional materials relating
to the Products shall be subject to CW’s prior written approval.

		(b)	Minimum Sales Goals. The Parties agree to the minimum sales goals outlined in Exhibit
C hereto. If Company fails to meet minimum sales goals in any such Contract Year, exclusivity granted to Company pursuant to Section
4 shall cease automatically and in advance of written notice; however, all other terms of the Agreement will continue in full force and
effect.

 

		11.	Royalties. 

(a)       Royalty
Payments. Within twenty (20) days following the end of each month of a Contract Year, the Company shall send to CW an itemized
report of all Net Sales revenue received by the Company from sales to third-party entities, including, but not limited to, direct-to-consumers,
distributors, and provincial boards, during the previous month (itemizing each sold Product by SKU, volume and price, noting any applicable
discounts permitted hereunder). Within forty-five (45) days following the end of each month of a Contract Year, the Company shall remit
to CW, in immediately available funds payment for ten percent (10%) for the Net Sales for such month in Canadian dollars.

(b)       Withholding
Tax. To the extent required by any applicable law, the Company may withhold from any royalty payment to CW an amount equivalent
to any applicable withholding tax. If the Canada Revenue Agency (“CRA”) or any other authority asserts a claim that
the Company did not properly withhold tax from amounts paid to CW, the Company will be responsible for that assessment.  If the assertion
is caused by CW (because the appropriate form was not delivered, was not properly executed, or because CW failed to notify the Company
of a change in circumstances that rendered a change to the withholding requirements) then CW shall indemnify the Company fully for all
amounts paid, directly or indirectly, by the Company as tax or otherwise, including penalties and interest.  In this situation, CW
retains the right to challenge the assessment at their own expense.  CW shall be granted the opportunity to submit the necessary
forms to the Company and CRA (when appropriate) to obtain the reduced treaty withholding rate. 

    Page 5 of 13

     

    

 

 

 

		12.	Audit Rights to Support Royalties. CW shall have the right, upon not less than twenty (20)
business days’ notice, no more than twice (2) in a Contract Year, and at CW’s sole cost and expense (all except as set forth
below), to inspect during usual business hours solely those portions of the books or records kept by the Company relating to Net Sales
during any quarter during the Term in connection with the payments made in sale of Products or transactions contemplated by the Agreement.
CW shall always be accompanied by a representative of Company while in Company’s facility or office. Each audit shall be conducted
by independent auditors and as efficiently as possible and with as little disruption to the business operations of Company as reasonably
possible. If during an audit it is found that the Company has underpaid the royalty owed CW by more than the greater of 10% or $10,000
in any annual period, then CW shall be entitled to the following: i) Company paying CW’s costs and expenses for carrying out the
audit and CW recovering an additional audit during the Contract Year. Should CW find through independent auditors that Company has underpaid
the royalty owed CW, per the above criteria, on two occasions during the Contract Year, it shall have a right to terminate the Agreement
for breach.

 

		13.	Term and Termination for Convenience. This Agreement shall commence on the Effective Date
and shall continue for a period of four (4) years until October 31, 2026, unless and until terminated as provided herein (the “Term”).
This Agreement may be terminated for convenience effective at any time on or after October 31, 2024, by either Party upon six (6) months’
prior written notice to the other Party.

 

		14.	Termination for Cause. Notwithstanding the foregoing,
this Agreement may be terminated by a Party at any time on immediate notice for cause as follows:

 

(a)       Termination
for Breach. This Agreement shall terminate within thirty (30) days after written notice of termination by one Party to the other
for a material breach of any provision of this Agreement, or for failure to meet Minimum Marketing and Sales Spend as provided in Section
10(a) or underpayments found under audit as provided in Section 12, unless such breach is cured within such thirty-day period (if curable).
Such termination shall not prejudice the rights of the non-breaching Party, who still shall have all of the rights and remedies
available to it in this Agreement, at law, in equity, or otherwise. Failure to pay a royalty or other sum when due hereunder shall be
deemed a material breach of this Agreement unless cured within such thirty-day period.

(b)
Termination for Bankruptcy. This Agreement shall terminate immediately and automatically if an assignment is made of either Party's
business for the benefit of creditors; if a receiver, trustee in bankruptcy, or like official is appointed to take all or part of either
Party's property; or if either Party ceases doing business in the ordinary course. 

(c)
Termination due to Regulatory Authority.

(i)
If a regulatory authority (including Health Canada or a provincial government wholesaler) or any third party challenges or refuses to
list or sell a Product and such challenge is reasonably likely, in the mutual determination of both Parties, to impact the commercial
viability of such Product, either Party may, upon thirty (30) days prior written notice to the other Party terminate its rights and obligations
under this Agreement with respect to the Products that are subject to such challenge; and 

 

(ii)
If a regulatory authority provides notice to a Party that it intends to seek the withdrawal or prohibition from the market of any
of the Products, the applicable Party, at its sole discretion, shall have the right, but not the obligation
to challenge the regulatory authority’s proposed action. If, following a challenge, the regulatory authority prevails in its effort
to withdraw from the market any of the Products, as evidenced by a final, non- appealable administrative or legal order, then either Party
may immediately upon written notice to the other Party terminate its rights and obligations under this Agreement with respect to the Products
that are subject to such withdrawal without penalty or recourse, relating to the Products that are subject to such withdrawal. In the
event that a Party determines not to challenge the proposed regulatory action, the other Party may immediately upon written notice to
such Party terminate its rights and obligations under this Agreement with respect to such Products.

    Page 6 of 13

     

    

 

		15.	Effect of Expiration or Termination. In the event
of expiration or termination of this Agreement:

		(a)	Outstanding Royalties and Inventory Sell-Off. The
effective date of termination shall constitute the final day of the Term and all royalties due for Net Sales revenues through that date
shall be paid by the Company to CW, after the termination date, in accordance with the terms hereof. The Company shall be entitled to
sell any Products remaining in its possession for a six (6) month period following such expiration or termination; except for terminations
pursuant to Section 13 (a) or (b), in which case the Company must immediately cease all sales activity of Products. CW shall be paid by
the Company all royalty payments due for any such sales of such remaining Products during such six (6) month period, even though occurring
after the date of termination of this Agreement. The Parties agree to take all steps reasonably required to give effect to the
termination of this Agreement, including providing for continued operation and utilization by the Company of the Materials and Products
to fulfill existing orders received prior to the effective date of termination.

 

		(b)	Survival: Upon termination of this Agreement, the
provisions of Sections 4, 15, 16, 18, 19, 20, 21, and 24 shall survive for a period of two (2) years. Termination or expiry of this Agreement
shall not affect any rights accrued prior to termination or expiration. For greater certainty, the termination or expiration of this Agreement
shall not prejudice or affect the rights of any Party against the other in respect of any breach of this Agreement or in respect of any
amounts payable in respect of any period prior to such termination or expiration. Termination of this Agreement will not release
either Party of the obligations and liabilities of such Party accruing up to the effective date of such termination.

 

		(c)	Holding Out. Subject to Company’s inventory
sell-off rights in Section 15(a) and all associated rights required to effect same, immediately upon any termination, the Company shall
cease to hold itself out as an authorized manufacturer or seller of CW. The license granted hereunder shall immediately terminate and
Company shall discontinue any and all use of all CW Trademarks (except as is necessary to sell out its remaining Products as provided
above) and shall remove all signs and other indication of its former affiliation with CW from its web site and elsewhere. Upon termination,
the Company promptly shall return all materials containing CW’s confidential information, Trademarks and/or intellectual property
to CW.

 

		16.	Indemnification; Liability.

		(a)	Each Party shall indemnify, defend, and hold harmless the other Party, its Affiliates, and their respective
directors, officers, representatives and employees from and against any and all damages, losses, liabilities costs and expenses of any
kind or nature, including without limitation, reasonable costs and attorney’s fees, in connection with any and all suits, investigations,
claims, or demands by third parties to the extent resulting from or arising out of (i) any breach by a Party, its Affiliates or their
respective officers, directors, employees, or representatives of any representation or warranty of that Party under this Agreement (ii)
any negligence or willful misconduct by a Party , its Affiliates or their respective officers, directors, employees, or representative.

		(b)	Other than in respect of claims: (a) for breaches of confidentiality, (b) for intellectual property infringement,
misappropriation or violations, (c) involving serious bodily harm or death, or (d) relating to payment obligations under this Agreement
no event shall (x) either Party be liable to the other Party under this Agreement for any indirect, consequential, special, incidental
or punitive damages, or loss of profit, loss of data or loss of savings, in connection with this Agreement; and (y) the aggregate liability
of either Party to the other Party under this Agreement exceed the amount of fees paid by Company to CW under this Agreement in the one
(1) year period immediately preceding the event giving rise to the claim. The foregoing exclusion and limitation of liability shall apply
regardless of the form of action, whether based in contract, tort (including negligence) or any other legal theory, whether such damage
or loss was foreseeable and whether or not such Party has been advised of the possibility of such.

    Page 7 of 13

     

    

 

		17.	Representations and Warranties.

 

(a) Each Party is duly organized
and validly existing under the laws of its jurisdiction of formation.

(b) Each Party is duly qualified
to do business and is in good standing in every jurisdiction in which such qualification is required for purposes of this Agreement.

(c) Each Party has the full right,
power, and authority to enter into this Agreement, to grant each other the rights set forth, including intellectual property rights,
and to perform its obligations hereunder.

		(d)	The execution of this Agreement has been duly authorized by all necessary action on the part of each Party.
This Agreement constitutes the legal, valid, and binding obligation of each Party in accordance with its terms.

		18.	Company Insurance. The Company shall maintain, during the term of this Agreement and for
two (2) years after the termination or expiration of this Agreement, Commercial General Liability insurance with appropriate endorsements,
with per-claim limitations and aggregate liability limitations in the amount of at least five (5) million dollars. The Company shall provide
CW with a certificate of such insurance promptly upon request and shall include CW as a named insured thereon upon request, if feasible.
The Company’s obligation to obtain the insurance specified herein does not waive or release the Company’s liabilities or duties
to indemnify.

		19.	Assignment and No Third Party Beneficiaries.

 

		(a)	Neither Party may assign this Agreement or delegate any of its duties or obligations hereunder to any
third party without the prior written consent of the other Party, not to be unreasonably withhold. Notwithstanding the foregoing, either
Party may be permitted to assign this Agreement in connection with a merger, acquisition, corporate reorganization, or sale of all or
substantially all of its assets upon notice to the other Party. This Agreement shall be binding upon, and shall inure to the benefit of,
all rightful assignees and successors to the Parties.

		(b)	The provisions of this Agreement are for the benefit of the Parties and not for any other person, including
without limitation the Cultivator or Distributor.

		20.	Dispute Resolution.

		(a)	Any dispute, controversy or claim arising out of or in connection with this Agreement, including any question
regarding its existence, validity, interpretation, breach or termination (a “Litigious Dispute”), shall be referred,
upon written notice (a “Notice of Dispute”) given by one Party to the other, to a senior executive from each Party.
The senior executives shall seek to resolve the Litigious Dispute on an amicable basis within thirty (30) days of the Notice of Dispute
being received. If both Parties agree, the Litigious Dispute may be referred to mediation before a mediator mutually agreed upon by the
Parties or, DR Institute of Canada, Inc. (the “ADRIC”). The Parties all equally share the costs of the mediator, the
mediation venue and the ADRIC.

 

    Page 8 of 13

     

    

		(b)	If the Litigious Dispute is not resolved within thirty (30) days of receipt of the Dispute Notice, the
Litigious Dispute shall be referred to and finally resolved by arbitration in accordance with the Arbitration Rules of ADRIC (the “Rules”)
but, subject to the agreement of both Parties, the ADRIC is not required to administer the arbitration (the “Arbitration”).
Unless otherwise agreed to in writing by the Parties:

 

		i.	the Arbitration shall be conducted before one (1) arbitrator mutually agreed upon by the Parties. If the
Parties are unable to agree upon an arbitrator within ten (10) Business Days of the commencement of the Arbitration, the arbitrator shall
be appointed in accordance with the Rules and the Arbitration shall proceed thereafter as an administered arbitration under the auspices
of ADRIC;

 

		ii.	the seat of the Arbitration shall be Toronto, Ontario, Canada;

 

		iii.	the language of the Arbitration shall be English;

 

		iv.	any award or determination of the arbitrator shall be final and binding on the Parties and there will
be no appeal on any ground, including, for certainty, any appeal on a question of law, a question of fact, or a question of mixed fact
and law; and

 

		v.	all matters relating to the Arbitration, including all documents created in the course of or for the purposes
of the Arbitration and any interim or final decision, order, or award in the Arbitration, shall be kept confidential and shall not be
disclosed by any Party to any third party (excluding their respective legal counsel and where necessary, financial advisors) without the
prior written consent of the other Party, or unless required by Applicable Laws.

 

		21.	Confidential Information. The Parties acknowledge
the continued existence and enforceability of the mutual non-disclosure agreement between the Parties dated January 5, 2022 in respect
of Confidential Information (as defined in such agreement) which may be shared between the Parties and their Affiliates and Representatives
(as defined in such agreement). The Parties confirm that the terms of such agreement shall remain in full force and effect and shall apply
in respect of the sharing of any Confidential Information hereunder

 

		22.	Press Release and Announcement. The Parties intend to issue a joint press release announcing
execution of this Agreement following execution. The wording of the joint press release and any other public announcements related to
this Agreement shall be approved in writing by both Parties prior to public disclosure.

 

		23.	Relationship of the Parties. Nothing in this Agreement shall be construed to create an agency,
partnership or joint venture between the Parties hereto, nor shall any similar relationship be deemed to exist between them. Neither Party
hereto shall represent itself to third parties as the agent, partner, or joint venturer of the other.

 

		24.	Intellectual Property. Except as expressly authorized in accordance with this Agreement,
neither Party, by the operation of this Agreement or otherwise, is hereby acquiring any right or interest in any intellectual property
right of the other Party, including but not limited to any trademark or trade name owned, used or claimed now or in the future by the
other Party. For the avoidance of any doubt, all intellectual property and proprietary rights, title and interest in or to the Products
or the CW Trademarks, or otherwise related thereto, are and shall remain the unique and exclusive property of CW. Company acknowledges
that the CW’s brand and all of its associated and derivative intellectual property and commercially sensitive information is solely
owned by CW, that Company has no ownership interest, encumbrance, lien, or title in the brand, its trademarks, its formulas, its specifications,
its trade dress, its recipes, its production processes, techniques, and/or any other intellectual property or proprietary information
(“CW Intellectual Property”). Company commits to respect and protect the CW Intellectual Property. Company will recognize
any unique process that is specific and exclusive in the industry to CW as CW Intellectual Property. However, Company cannot be constrained
from the broader use of typical industry practices and processes by their use in the making of Products. CW recognizes that Company, as
a manufacturer, is knowledgeable in the field and that certain generic and generally used processes and knowledge cannot become the property
of CW or any other entity. Company agrees that no express or implied licenses or other rights relating to any CW Intellectual Property
are provided to Company hereunder, other than to the extent necessary to complete the relevant activities of this Agreement or as otherwise
specifically set forth herein. Title in all CW Intellectual Property shall remain at all times in CW. Company agrees that CW Intellectual
Property shall: (i) only be used as specified in writing by CW and not for any other purpose; (ii) only be made accessible to those employees
of Company who need access in order to complete the relevant activities of this Agreement; (iii} be used in compliance at all times with
all Applicable Laws; (iv) be carefully secured and not be transferred to any affiliate or third party without the explicit prior written
consent of CW; (v) not be reverse engineered; and (vi) not be subjected to testing procedures not specifically requested by CW as part
of this Agreement. All rights in and to the processes, procedures, techniques, know-how and trade secrets relating to the manufacturing,
packaging, labelling, and testing of cannabis used in the production of the Products shall remain the exclusive property of Company (“Company
Intellectual Property”). CW acknowledges that CW has no ownership interest, encumbrance, lien, or title in the Company Intellectual
Property. CW commits to respect and protect the Company Intellectual Property. CW will recognize any unique process that is specific and
exclusive in the industry to Company as Company Intellectual Property

    Page 9 of 13

     

    

 

 

 

		25.	Foreign Corrupt Practices Act. The Company recognizes
that CW is a United States corporation, and as such has certain legal and ethical responsibilities to avoid involvement with certain types
of transactions. The Company hereby represents and warrants that it has not, and covenants that it shall not during the term of this Agreement,
directly or indirectly, give, offer, authorize, pay or promise to pay any money or anything of value to any Foreign Official (defined
below), or to any political party or party official or candidate for political office, for the purpose of influencing any act or inducing
such Foreign Official or other person or entity to use his influence to assist the Company or CW in obtaining or retaining any sales or
business relating to the Products. For purposes of this paragraph, "Foreign Official" shall mean an officer or employee
of a government (other than the United States) or any department, agency or instrumentality thereof, or any person or entity acting in
an official capacity for or on behalf of any such government or department, agency or instrumentality.

		26.	Insider Trading. Both Parties are owned by parents
whose stock is publicly traded. It is possible that, in the course of its actions hereunder, a Party might come into contact with material
undisclosed information about the other Party. Each Party understands that the securities laws of Canada and the United States both forbid
buying, selling or otherwise trading publicly traded stock upon such information until it becomes a matter of public record, and will
be responsible for actions taken by any of its Representatives in violation thereof.

 

		27.	Entire Agreement; Further Assurances. This Agreement comprises the full and entire understanding
and agreement between the parties with regard to the subject matter hereof, and supersedes all oral or written agreements and understandings
with regard to such subject matter hereof. Each of Company and CW will from time to time execute
and deliver all such further documents and instruments and do all acts and things as the other Party may reasonably require to effectively
carry out or better evidence or perfect the full intent and meaning of this Agreement.

    Page 10 of 13

     

    

 

		28.	Severability. In case any provision of this Agreement shall be invalid, illegal or unenforceable,
such provision shall be reformed to the extent necessary to permit enforcement thereof, and the validity, legality and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby.

 

		29.	Equitable Remedies. Each Party hereto hereby confirms that damages at law may be an inadequate
remedy for the breach or threatened breach of this Agreement and agrees that, in the event of a breach or threatened breach by a Party
of any provision hereof, the other Party's rights and obligations hereunder shall be enforceable by specific performance, injunction,
or other equitable remedy, in addition to and not in lieu of any rights to damages at law or other rights provided by statute or otherwise
for a breach or threatened breach of any provision hereof. Accordingly, each Party hereto hereby waives and agrees not to assert any objection
to such equitable relief based upon the purported existence of an adequate remedy at law, notwithstanding that another Party may also
assert claims for damages at law or other claims as an alternative to, or in addition to, such equitable relief.

		30.	Notices. Notices and other communications hereunder shall be given to the parties at their
respective address as set forth on the initial paragraph hereof, or to such other addresses as to which the parties may subsequently notify
each other in writing. All notices and other communications hereunder shall be in writing, and shall be deemed to have been given at the
date of actual receipt, or when actual delivery to such address or tender of delivery has been confirmed in writing by an unaffiliated
delivery service. E-mails and other forms of electronic communication shall constitute valid notice (or communication) only if receipt
thereof is thereafter acknowledged and confirmed by the recipient, by means of the same medium or another medium permitted hereunder.

 

		31.	Governing Law. This Agreement shall be governed and
construed in accordance with the laws of the Province of Ontario and the federal statutes of Canada applicable therein, and each Party
agree that any litigation arising out of or relating to this Agreement will be submitted to the exclusive jurisdiction of the courts of
the Province of Ontario, Canada, except that a Party may enforce a decision of such courts, and may seek injunctive relief only, in any
court with jurisdiction over the other Party. 

 

		32.	Force Majeure. A Party shall be excused for any failure or delay in performing any of its
obligations under this Agreement, if such failure or delay is caused by Force Majeure, provided that such affected Party shall (a) promptly
notify the other Party in writing of the occurrence or circumstance upon which it intends to rely to excuse its performance, and (b) use
commercially reasonable efforts to promptly resume performance after the cause of such delay is removed. For purposes of this Agreement,
“Force Majeure” shall mean any act of God, accident, explosion, fire, epidemic and pandemic, storm, earthquake, flood,
drought, riot, insurrection, embargo, civil commotion, war, act of war, terrorism, act or order of any Governmental Authority or inability
to obtain or delay in the delivery of raw materials, parts or completed merchandise by the supplier, strikes or other labor difficulties,
or any other cause not under the control of the affected Party. In the event that the Force Majeure shall continue for a period of sixty
(60) days, either Party shall have the right to immediately terminate this Agreement following written notice to the other Party.

 

		33.	Amendments. Changes, amendments, or modification in, or additions to, any provision of this
Agreement shall be made only by a written instrument executed by both of the Parties.

 

    Page 11 of 13

     

    

		34.	Delays or Omissions; Waivers. No delay or omission to exercise any right, power or remedy
inuring to any Party, upon any breach or default of any Party under this Agreement, shall impair any such right, power or remedy of such
Party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach
or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default
theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any Party of any
breach or default under this Agreement, or any waiver on the part of any Party of any provisions or conditions of this Agreement must
be made in writing by the Party to be charged therewith and shall be effective only to the extent specifically set forth in such writing.
All remedies either under this Agreement or by law or otherwise afforded to any holder, shall be cumulative and not alternative.

		35.	Authorization. Each Party hereby represents and warrants to the other that it is duly constituted
as a legal entity in good standing in the jurisdiction of its organization, that it has all necessary authority to enter into this Agreement,
that doing so will not violate the provisions of any agreement or obligation to which such Party is subject, and that the signer of this
Agreement on behalf of such Party is duly authorized to do so.

 

		36.	Captions. Captions are for convenience only and shall not be deemed to be a part of this
Agreement, nor shall be taken into any consideration in the interpretation hereof.

 

		37.	Counterparts. This Agreement may be executed in any number of counterparts, including electronic,
each of which shall constitute an original, but which taken together shall constitute one instrument.

 

		38.	Construction. Any illegal or invalid provision shall
be construed by a court of competent jurisdiction to have the broadest scope permissible under the law of said jurisdiction, and if no
validating construction is possible, shall be severable, and all other provisions hereof shall remain in full force and effect. 

 

[signatures on following page]

 

    Page 12 of 13

     

    

 

IN WITNESS WHEREOF, the Parties
hereunto set their hands and seals to this Manufacturing and Sales Licensing Agreement as of the date set forth below.

 

 

CHARLOTTE’S WEB, INC.

 

 

 

 

(Signature): By: /s/ Jacques Tortoroli

 

Name and title of authorized signatory: Jacques Tortoroli, CEO

E-mail: 

Date: November 1, 2022

 

 

APHRIA INC.

 

 

 

 

(Signature): By: /s/ Blair MacNeil

 

Name and title of authorized signatory: Blair MacNeil, President

E-mail:

Date: November 1, 2022

 

 

 

Page
13 of 13Exhibit 10.42

 

NEITHER
THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE
HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM,
THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA
FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.

 

	Principal
    Amount: $53,750.00	Issue
    Date: August 23, 2022

Purchase
Price: $53,750.00

CONVERTIBLE
PROMISSORY NOTE

 

FOR
VALUE RECEIVED, GZ6G Technologies Corp., a Nevada corporation (hereinafter called the “Borrower”), hereby promises
to pay to the order of 1800 DIAGONAL LENDING LLC, a Virginia limited liability company, or registered assigns (the “Holder”)
the sum of $53,750.00 together with any interest as set forth herein, on August 23, 2023 (the “Maturity Date”), and to pay
interest on the unpaid principal balance hereof at the rate of ten percent (10%)(the “Interest Rate”) per annum from the
date hereof (the “Issue Date”) until the same becomes due and payable, whether at maturity or upon acceleration or by prepayment
or otherwise. This Note may not be prepaid in whole or in part except as otherwise explicitly set forth herein. Any amount of principal
or interest on this Note which is not paid when due shall bear interest at the rate of twenty two percent (22%) per annum from the due
date thereof until the same is paid (“Default Interest”). Interest shall be computed on the basis of a 365 day year and the
actual number of days elapsed. Interest shall commence accruing on the Issue Date but shall not be payable until the Note becomes payable
(whether at Maturity Date or upon acceleration or by prepayment). All payments due hereunder (to the extent not converted into common
stock, $0.001 par value per share (the “Common Stock”) in accordance with the terms hereof) shall be made in lawful money
of the United States of America. All payments shall be made at such address as the Holder shall hereafter give to the Borrower by written
notice made in accordance with the provisions of this Note. Each capitalized term used herein, and not otherwise defined, shall have
the meaning ascribed thereto in that certain Securities Purchase Agreement dated the date hereof, pursuant to which this Note was originally
issued (the “Purchase Agreement”).

 

This
Note is free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive
rights or other similar rights of shareholders of the Borrower and will not impose personal liability upon the holder thereof.

 

     

     

    

 

The
following terms shall apply to this Note:

 

Article
I. CONVERSION RIGHTS

 

1.1 
Conversion Right. The Holder shall have the right from time to time, and at any time during the period beginning on the date which
is one hundred eighty (180) days following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date
of payment of the Default Amount (as defined in Article III), each in respect of the remaining outstanding amount of this Note to convert
all or any part of the outstanding and unpaid amount of this Note into fully paid and non-assessable shares of Common Stock, as such
Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Borrower into which such Common Stock
shall hereafter be changed or reclassified at the conversion price (the “Conversion Price”) determined as provided herein
(a “Conversion”); provided, however, that in no event shall the Holder be entitled to convert any portion of
this Note in excess of that portion of this Note upon conversion of which the sum of (1) the number of shares of Common Stock beneficially
owned by the Holder and its affiliates (other than shares of Common Stock which may be deemed beneficially owned through the ownership
of the unconverted portion of the Notes or the unexercised or unconverted portion of any other security of the Borrower subject to a
limitation on conversion or exercise analogous to the limitations contained herein) and (2) the number of shares of Common Stock issuable
upon the conversion of the portion of this Note with respect to which the determination of this proviso is being made, would result in
beneficial ownership by the Holder and its affiliates of more than 4.99% of the outstanding shares of Common Stock. For purposes of the
proviso to the immediately preceding sentence, beneficial ownership shall be determined in accordance with Section 13(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and Regulations 13D-G thereunder, except as otherwise provided in
clause (1) of such proviso. The beneficial ownership limitations on conversion as set forth in the section may NOT be waived by the
Holder. The number of shares of Common Stock to be issued upon each conversion of this Note shall be determined by dividing the Conversion
Amount (as defined below) by the applicable Conversion Price then in effect on the date specified in the notice of conversion, in the
form attached hereto as Exhibit A (the “Notice of Conversion”), delivered to the Borrower by the Holder in accordance with
Section 1.4 below; provided that the Notice of Conversion is submitted by facsimile or e-mail (or by other means resulting in, or reasonably
expected to result in, notice) to the Borrower before 6:00 p.m., New York, New York time on such conversion date (the “Conversion
Date”); however, if the Notice of Conversion is sent after 6:00pm, New York, New York time the Conversion Date shall be the next
business day. The term “Conversion Amount” means, with respect to any conversion of this Note, the sum of (1) the principal
amount of this Note to be converted in such conversion plus (2) at the Holder’s option, accrued and unpaid interest, if
any, on such principal amount at the interest rates provided in this Note to the Conversion Date, plus (3) at the Holder’s
option, Default Interest, if any, on the amounts referred to in the immediately preceding clauses (1) and/or (2) plus (4) at the
Holder’s option, any amounts owed to the Holder pursuant to Sections 1.4 hereof.

 

1.2 Conversion
Price. The Conversion Price shall equal the Variable Conversion Price (as defined herein)(subject to equitable adjustments for stock
splits, stock dividends or rights offerings by the Borrower relating to the Borrower’s securities or the securities of any subsidiary
of the Borrower, combinations, recapitalization, reclassifications, extraordinary distributions and similar events). The “Variable
Conversion Price” shall mean 65% multiplied by the Market Price (as defined herein) (representing a discount rate of 35%). “Market
Price” means the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day period ending on
the latest complete Trading Day prior to the Conversion Date. “Trading Price” means, for any security as of any date, the
closing bid price on the OTCQB, OTCQX, Pink Sheets electronic quotation system or applicable trading market (the “OTC”) as
reported by a reliable reporting service (“Reporting Service”) designated by the Holder (i.e. Bloomberg) or, if the OTC is
not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading
market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners,
the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets”. If the
Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market
value as mutually determined by the Borrower and the holders of a majority in interest of the Notes being converted for which the calculation
of the Trading Price is required in order to determine the Conversion Price of such Notes. “Trading Day” shall mean any day
on which the Common Stock is tradable for any period on the OTC, or on the principal securities exchange or other securities market on
which the Common Stock is then being traded.

 

    2

     

    

 

1.3 Authorized
Shares. The Borrower covenants that during the period the conversion right exists, the Borrower will reserve from its authorized
and unissued Common Stock a sufficient number of shares, free from preemptive rights, to provide for the issuance of Common Stock upon
the full conversion of this Note issued pursuant to the Purchase Agreement. The Borrower is required at all times to have authorized
and reserved six times the number of shares that would be issuable upon full conversion of the Note (assuming that the 4.99% limitation
set forth in Section 1.1 is not in effect)(based on the respective Conversion Price of the Note (as defined in Section 1.2) in effect
from time to time, initially 18,240,950 shares)(the “Reserved Amount”).
The Reserved Amount shall be increased (or decreased with the written consent of the Holder) from time to time in accordance with the
Borrower’s obligations hereunder. The Borrower represents that upon issuance, such shares will be duly and validly issued, fully
paid and non-assessable. In addition, if the Borrower shall issue any securities or make any change to its capital structure which would
change the number of shares of Common Stock into which the Notes shall be convertible at the then current Conversion Price, the Borrower
shall at the same time make proper provision so that thereafter there shall be a sufficient number of shares of Common Stock authorized
and reserved, free from preemptive rights, for conversion of the outstanding Note. The Borrower (i) acknowledges that it has irrevocably
instructed its transfer agent to issue certificates for the Common Stock issuable upon conversion of this Note, and (ii) agrees
that its issuance of this Note shall constitute full authority to its officers and agents who are charged with the duty of executing
stock certificates to execute and issue the necessary certificates for shares of Common Stock in accordance with the terms and conditions
of this Note.

 

If,
at any time the Borrower does not maintain the Reserved Amount it will be considered an Event of Default under Section 3.2 of the Note.

 

1.4 Method
of Conversion.

 

(a) Mechanics
of Conversion. As set forth in Section 1.1 hereof, from time to time, and at any time during the period beginning on the date which
is one hundred eighty (180) days following the date of this Note and ending on the later of: (i) the Maturity Date and (ii) the date
of payment of the Default Amount, this Note may be converted by the Holder in whole or in part at any time from time to time after the
Issue Date, by (A) submitting to the Borrower a Notice of Conversion (by facsimile, e-mail or other reasonable means of communication
dispatched on the Conversion Date prior to 6:00 p.m., New York, New York time) and (B) subject to Section 1.4(b), surrendering this
Note at the principal office of the Borrower (upon payment in full of any amounts owed hereunder).

 

(b) Surrender
of Note Upon Conversion. Notwithstanding anything to the contrary set forth herein, upon conversion of this Note in accordance with
the terms hereof, the Holder shall not be required to physically surrender this Note to the Borrower unless the entire unpaid principal
amount of this Note is so converted. The Holder and the Borrower shall maintain records showing the principal amount so converted and
the dates of such conversions or shall use such other method, reasonably satisfactory to the Holder and the Borrower, so as not to require
physical surrender of this Note upon each such conversion.

 

    3

     

    

 

(c) Delivery
of Common Stock Upon Conversion. Upon receipt by the Borrower from the Holder of a facsimile transmission or e-mail (or other reasonable
means of communication) of a Notice of Conversion meeting the requirements for conversion as provided in this Section 1.4, the Borrower
shall issue and deliver or cause to be issued and delivered to or upon the order of the Holder certificates for the Common Stock issuable
upon such conversion within three (3) business days after such receipt (the “Deadline”) (and, solely in the case of conversion
of the entire unpaid principal amount hereof, surrender of this Note) in accordance with the terms hereof and the Purchase Agreement.
Upon receipt by the Borrower of a Notice of Conversion, the Holder shall be deemed to be the holder of record of the Common Stock issuable
upon such conversion, the outstanding principal amount and the amount of accrued and unpaid interest on this Note shall be reduced to
reflect such conversion, and, unless the Borrower defaults on its obligations hereunder, all rights with respect to the portion of this
Note being so converted shall forthwith terminate except the right to receive the Common Stock or other securities, cash or other assets,
as herein provided, on such conversion. If the Holder shall have given a Notice of Conversion as provided herein, the Borrower’s
obligation to issue and deliver the certificates for Common Stock shall be absolute and unconditional, irrespective of the absence of
any action by the Holder to enforce the same, any waiver or consent with respect to any provision thereof, the recovery of any judgment
against any person or any action to enforce the same, any failure or delay in the enforcement of any other obligation of the Borrower
to the holder of record, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder
of any obligation to the Borrower, and irrespective of any other circumstance which might otherwise limit such obligation of the Borrower
to the Holder in connection with such conversion.

 

(d) Delivery
of Common Stock by Electronic Transfer. In lieu of delivering physical certificates representing the Common Stock issuable upon conversion,
provided the Borrower is participating in the Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”)
program, upon request of the Holder and its compliance with the provisions set forth herein, the Borrower shall use its best efforts
to cause its transfer agent to electronically transmit the Common Stock issuable upon conversion to the Holder by crediting the account
of Holder’s Prime Broker with DTC through its Deposit Withdrawal Agent Commission (“DWAC”) system.

 

(e) Failure
to Deliver Common Stock Prior to Deadline. Without in any way limiting the Holder’s right to pursue other remedies, including
actual damages and/or equitable relief, the parties agree that if delivery of the Common Stock issuable upon conversion of this Note
is not delivered by the Deadline due to action and/or inaction of the Borrower, the Borrower shall pay to the Holder $2,000 per day in
cash, for each day beyond the Deadline that the Borrower fails to deliver such Common Stock (the “Fail to Deliver Fee”);
provided; however that the Fail to Deliver Fee shall not be due if the failure is: (i) a result of a third party (i.e., transfer agent;
and not the result of any failure to pay such transfer agent) despite the best efforts of the Borrower to effect delivery of such Common
Stock; and/or (ii) not the result of the Borrower purposely, willfully and intentionally hindering the conversion. Such cash amount shall
be paid to Holder by the fifth day of the month following the month in which it has accrued or, at the option of the Holder (by written
notice to the Borrower by the first day of the month following the month in which it has accrued), shall be added to the principal amount
of this Note, in which event interest shall accrue thereon in accordance with the terms of this Note and such additional principal amount
shall be convertible into Common Stock in accordance with the terms of this Note. The Borrower agrees that the right to convert is a
valuable right to the Holder. The damages resulting from a failure, attempt to frustrate, interference with such conversion right are
difficult if not impossible to qualify. Accordingly, the parties acknowledge that the liquidated damages provision contained in this
Section 1.4(e) are justified.

 

    4

     

    

 

1.5 
Concerning the Shares. The shares of Common Stock issuable upon conversion of this Note may not be sold or transferred unless:
(i) such shares are sold pursuant to an effective registration statement under the Act or (ii) the Borrower or its transfer agent shall
have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for opinions of counsel
in comparable transactions) to the effect that the shares to be sold or transferred may be sold or transferred pursuant to an exemption
from such registration (such as Rule 144 or a successor rule) (“Rule 144”); or (iii) such shares are transferred to an “affiliate”
(as defined in Rule 144) of the Borrower who agrees to sell or otherwise transfer the shares only in accordance with this Section 1.5
and who is an Accredited Investor (as defined in the Purchase Agreement).

 

Any
restrictive legend on certificates representing shares of Common Stock issuable upon conversion of this Note shall be removed and the
Borrower shall issue to the Holder a new certificate therefore free of any transfer legend if the Borrower or its transfer agent shall
have received an opinion of counsel from Holder’s counsel, in form, substance and scope customary for opinions of counsel in comparable
transactions, to the effect that (i) a public sale or transfer of such Common Stock may be made without registration under the Act, which
opinion shall be accepted by the Company so that the sale or transfer is effected; or (ii) in the case of the Common Stock issuable upon
conversion of this Note, such security is registered for sale by the Holder under an effective registration statement filed under the
Act; or otherwise may be sold pursuant to an exemption from registration. In the event that the Company does not reasonably accept the
opinion of counsel provided by the Holder with respect to the transfer of Securities pursuant to an exemption from registration (such
as Rule 144), at the Deadline, it will be considered an Event of Default pursuant to Section 3.2 of the Note.

 

1.6 Effect
of Certain Events.

 

(a) Effect
of Merger, Consolidation, Etc. At the option of the Holder, the sale, conveyance or disposition of all or substantially all of the
assets of the Borrower, the effectuation by the Borrower of a transaction or series of related transactions in which more than 50% of
the voting power of the Borrower is disposed of, or the consolidation, merger or other business combination of the Borrower with or into
any other Person (as defined below) or Persons when the Borrower is not the survivor shall be deemed to be an Event of Default (as defined
in Article III) pursuant to which the Borrower shall be required to pay to the Holder upon the consummation of and as a condition to
such transaction an amount equal to the Default Amount (as defined in Article III). “Person” shall mean any individual, corporation,
limited liability company, partnership, association, trust or other entity or organization.

 

(b) Adjustment
Due to Merger, Consolidation, Etc. If, at any time when this Note is issued and outstanding and prior to conversion of all of the
Note, there shall be any merger, consolidation, exchange of shares, recapitalization, reorganization, or other similar event, as a result
of which shares of Common Stock of the Borrower shall be changed into the same or a different number of shares of another class or classes
of stock or securities of the Borrower or another entity, or in case of any sale or conveyance of all or substantially all of the assets
of the Borrower other than in connection with a plan of complete liquidation of the Borrower, then the Holder of this Note shall thereafter
have the right to receive upon conversion of this Note, upon the basis and upon the terms and conditions specified herein and in lieu
of the shares of Common Stock immediately theretofore issuable upon conversion, such stock, securities or assets which the Holder would
have been entitled to receive in such transaction had this Note been converted in full immediately prior to such transaction (without
regard to any limitations on conversion set forth herein), and in any such case appropriate provisions shall be made with respect to
the rights and interests of the Holder of this Note to the end that the provisions hereof (including, without limitation, provisions
for adjustment of the Conversion Price and of the number of shares issuable upon conversion of the Note) shall thereafter be applicable,
as nearly as may be practicable in relation to any securities or assets thereafter deliverable upon the conversion hereof. The Borrower
shall not affect any transaction described in this Section 1.6(b) unless (a) it first gives, to the extent practicable, ten (10) days
prior written notice (but in any event at least five (5) days prior written notice) of the record date of the special meeting of shareholders
to approve, or if there is no such record date, the consummation of, such merger, consolidation, exchange of shares, recapitalization,
reorganization or other similar event or sale of assets (during which time the Holder shall be entitled to convert this Note) and (b)
the resulting successor or acquiring entity (if not the Borrower) assumes by written instrument the obligations of this Note. The above
provisions shall similarly apply to successive consolidations, mergers, sales, transfers or share exchanges.

 

    5

     

    

 

(c) Adjustment
Due to Distribution. If the Borrower shall declare or make any distribution of its assets (or rights to acquire its assets) to holders
of Common Stock as a dividend, stock repurchase, by way of return of capital or otherwise (including any dividend or distribution to
the Borrower’s shareholders in cash or shares (or rights to acquire shares) of capital stock of a subsidiary (i.e., a spin-off))
(a “Distribution”), then the Holder of this Note shall be entitled, upon any conversion of this Note after the date of record
for determining shareholders entitled to such Distribution, to receive the amount of such assets which would have been payable to the
Holder with respect to the shares of Common Stock issuable upon such conversion had such Holder been the holder of such shares of Common
Stock on the record date for the determination of shareholders entitled to such Distribution.

 

1.7 Prepayment.
Notwithstanding anything to the contrary contained in this Note, at any time during the periods set forth on the table immediately following
this paragraph (the “Prepayment Periods”), the Borrower shall have the right, exercisable on not more than three (3) Trading
Days prior written notice to the Holder of the Note to prepay the outstanding Note (principal and accrued interest), in full, in accordance
with this Section 1.7. Any notice of prepayment hereunder (an “Optional Prepayment Notice”) shall be delivered to the Holder
of the Note at its registered addresses and shall state: (1) that the Borrower is exercising its right to prepay the Note, and (2) the
date of prepayment which shall be not more than three (3) Trading Days from the date of the Optional Prepayment Notice. On the date fixed
for prepayment (the “Optional Prepayment Date”), the Borrower shall make payment of the Optional Prepayment Amount (as defined
below) to Holder, or upon the direction of the Holder as specified by the Holder in a writing to the Borrower (which shall direction
to be sent to Borrower by the Holder at least one (1) business day prior to the Optional Prepayment Date). If the Borrower exercises
its right to prepay the Note, the Borrower shall make payment to the Holder of an amount in cash equal to the percentage (“Prepayment
Percentage”) as set forth in the table immediately following this paragraph opposite the applicable Prepayment Period, multiplied
by the sum of: (w) the then outstanding principal amount of this Note plus (x) accrued and unpaid interest on the unpaid
principal amount of this Note to the Optional Prepayment Date plus (y) Default Interest, if any, on the amounts referred to in
clauses (w) and (x) plus (z) any amounts owed to the Holder pursuant to Section 1.4 hereof (the “Optional Prepayment Amount”).
If the Borrower delivers an Optional Prepayment Notice and fails to pay the Optional Prepayment Amount due to the Holder of the Note
within two (2) business days following the Optional Prepayment Date, the Borrower shall forever forfeit its right to prepay the Note
pursuant to this Section 1.7.

 

	Prepayment
    Period	Prepayment
    Percentage
	1.
    The period beginning on the Issue Date and ending on the date which is thirty (30) days following the Issue Date.	115%
	2.
    The period beginning on the date that is thirty-one (31) day from the Issue Date and ending sixty (60) days following the Issue
    Date.	120%
	3.
    The period beginning on the date that is sixty-one (61) day from the Issue Date and ending one hundred eighty (180) days following
    the Issue Date.	125%

 

    6

     

    

 

After
the expiration of the Prepayment Periods set forth above, the Borrower may submit an Optional Prepayment Notice to the Holder. Upon receipt
by the Holder of the Optional Prepayment Notice post Prepayment Periods, the prepayment shall be subject to the Holder’s and the
Borrower’s agreement with respect to the applicable Prepayment Percentage.

 

Notwithstanding
anything contained herein to the contrary, the Holder’s conversion rights herein shall not be affected in any way until the Note
is fully paid (funds received by the Holder) pursuant to an Optional Prepayment Notice.

 

Article
II.  CERTAIN COVENANTS

 

2.1 Sale
of Assets. So long as the Borrower shall have any obligation under this Note, the Borrower shall not, without the Holder’s
written consent, sell, lease or otherwise dispose of any significant portion of its assets outside the ordinary course of business. Any
consent to the disposition of any assets may be conditioned on a specified use of the proceeds of disposition.

 

Article
III.  EVENTS OF DEFAULT

 

If
any of the following events of default (each, an “Event of Default”) shall occur:

 

3.1 Failure
to Pay Principal and Interest. The Borrower fails to pay the principal hereof or interest thereon when due on this Note, whether
at maturity or upon acceleration and such breach continues for a period of five (5) days after written notice from the Holder.

 

3.2 Conversion
and the Shares. The Borrower fails to issue shares of Common Stock to the Holder (or announces or threatens in writing that it will
not honor its obligation to do so) upon exercise by the Holder of the conversion rights of the Holder in accordance with the terms of
this Note, fails to transfer or cause its transfer agent to transfer (issue) (electronically or in certificated form) any certificate
for shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to this Note as and when required by this Note,
the Borrower directs its transfer agent not to transfer or delays, impairs, and/or hinders its transfer agent in transferring (or issuing)
(electronically or in certificated form) any certificate for shares of Common Stock to be issued to the Holder upon conversion of or
otherwise pursuant to this Note as and when required by this Note, or fails to remove (or directs its transfer agent not to remove or
impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions
in respect thereof) on any certificate for any shares of Common Stock issued to the Holder upon conversion of or otherwise pursuant to
this Note as and when required by this Note (or makes any written announcement, statement or threat that it does not intend to honor
the obligations described in this paragraph) and any such failure shall continue uncured (or any written announcement, statement or threat
not to honor its obligations shall not be rescinded in writing) for three (3) business days after the Holder shall have delivered a Notice
of Conversion. It is an obligation of the Borrower to remain current in its obligations to its transfer agent. It shall be an event of
default of this Note, if a conversion of this Note is delayed, hindered or frustrated due to a balance owed by the Borrower to its transfer
agent. If at the option of the Holder, the Holder advances any funds to the Borrower’s transfer agent in order to process a conversion,
such advanced funds shall be paid by the Borrower to the Holder within forty-eight (48) hours of a demand from the Holder.

 

    7

     

    

 

3.3 Breach
of Covenants. The Borrower breaches any material covenant or other material term or condition contained in this Note and any collateral
documents including but not limited to the Purchase Agreement and such breach continues for a period of twenty (20) days after written
notice thereof to the Borrower from the Holder.

 

3.4 Breach
of Representations and Warranties. Any representation or warranty of the Borrower made herein or in any agreement, statement or certificate
given in writing pursuant hereto or in connection herewith (including, without limitation, the Purchase Agreement), shall be false or
misleading in any material respect when made and the breach of which has (or with the passage of time will have) a material adverse effect
on the rights of the Holder with respect to this Note or the Purchase Agreement.

 

3.5 Receiver
or Trustee. The Borrower or any subsidiary of the Borrower shall make an assignment for the benefit of creditors, or apply for or
consent to the appointment of a receiver or trustee for it or for a substantial part of its property or business, or such a receiver
or trustee shall otherwise be appointed.

 

3.6 Bankruptcy.
Bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any
bankruptcy law or any law for the relief of debtors shall be instituted by or against the Borrower or any subsidiary of the Borrower.

 

3.7 Delisting
of Common Stock. The Borrower shall fail to maintain the listing of the Common Stock on at least one of the OTC (which specifically
includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market,
the Nasdaq SmallCap Market, the New York Stock Exchange, or the American Stock Exchange.

 

3.8 Failure
to Comply with the Exchange Act. The Borrower shall fail to comply with the reporting requirements of the Exchange Act; and/or the
Borrower shall cease to be subject to the reporting requirements of the Exchange Act (the filing of a Form 15 with the SEC is an immediate
Event of Default).

 

3.9 Liquidation.
Any dissolution, liquidation, or winding up of Borrower or any substantial portion of its business.

 

3.10Cessation
of Operations.Any cessation of operations by Borrower or Borrower admits it is otherwise generally unable to pay its debts as
such debts become due, provided, however, that any disclosure of the Borrower’s ability to continue as a “going concern”
shall not be an admission that the Borrower cannot pay its debts as they become due.

 

3.11Financial
Statement Restatement.The restatement of any financial statements filed by the Borrower with the SEC at any time after 180 days
after the Issuance Date for any date or period until this Note is no longer outstanding, if the result of such restatement would, by
comparison to the un-restated financial statement, have constituted a material adverse effect on the rights of the Holder with respect
to this Note or the Purchase Agreement.

 

3.12 
Replacement of Transfer Agent. In the event that the Borrower proposes to replace its transfer agent, the Borrower fails to provide,
prior to the effective date of such replacement, a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered
pursuant to the Purchase Agreement (including but not limited to the provision to irrevocably reserve shares of Common Stock in the Reserved
Amount) signed by the successor transfer agent to Borrower and the Borrower.

 

    8

     

    

 

3.13 Cross-Default. 
Notwithstanding anything to the contrary contained in this Note or the other related or companion documents, a breach or default by the
Borrower of any covenant or other term or condition contained in any of the Other Agreements, after the passage of all applicable notice
and cure or grace periods, shall, at the option of the Holder, be considered a default under this Note and the Other Agreements, in which
event the Holder shall be entitled (but in no event required) to apply all rights and remedies of the Holder under the terms of this
Note and the Other Agreements by reason of a default under said Other Agreement or hereunder. “Other Agreements” means, collectively,
all agreements and instruments between, among or by: (1) the Borrower, and, or for the benefit of, (2) the Holder and any affiliate
of the Holder, including, without limitation, promissory notes; provided, however, the term “Other Agreements” shall not
include the related or companion documents to this Note. Each of the loan transactions will be cross-defaulted with each other loan transaction
and with all other existing and future debt of Borrower to the Holder.

 

Upon
the occurrence and during the continuation of any Event of Default specified in Section 3.1 (solely with respect to failure to pay the
principal hereof or interest thereon when due at the Maturity Date), the Note shall become immediately due and payable and the Borrower
shall pay to the Holder, in full satisfaction of its obligations hereunder, an amount equal to the Default Amount (as defined herein). 
UPON THE OCCURRENCE AND DURING THE CONTINUATION OF ANY EVENT OF DEFAULT SPECIFIED IN SECTION 3.2, THE NOTE SHALL BECOME IMMEDIATELY DUE
AND PAYABLE AND THE BORROWER SHALL PAY TO THE HOLDER, IN FULL SATISFACTION OF ITS OBLIGATIONS HEREUNDER, AN AMOUNT EQUAL TO: (Y) THE
DEFAULT AMOUNT (AS DEFINED HEREIN); MULTIPLIED BY (Z) TWO (2). Upon the occurrence and during the continuation of any Event of Default
specified in Sections 3.1 (solely with respect to failure to pay the principal hereof or interest thereon when due on this Note upon
a Trading Market Prepayment Event pursuant to Section 1.7 or upon acceleration), 3.3, 3.4, 3.7, 3.8, 3.10, 3.11, 3.12, 3.13, and/or 3.14
exercisable through the delivery of written notice to the Borrower by such Holders (the “Default Notice”), and upon the occurrence
of an Event of Default specified the remaining sections of Articles III (other than failure to pay the principal hereof or interest thereon
at the Maturity Date specified in Section 3,1 hereof), the Note shall become immediately due and payable and the Borrower shall pay to
the Holder, in full satisfaction of its obligations hereunder, an amount equal to 150% times the sum of (w) the then outstanding
principal amount of this Note plus (x) accrued and unpaid interest on the unpaid principal amount of this Note to the date of
payment (the “Mandatory Prepayment Date”) plus (y) Default Interest, if any, on the amounts referred to in clauses
(w) and/or (x) plus (z) any amounts owed to the Holder pursuant to Sections 1.3 and 1.4(g) hereof (the then outstanding principal
amount of this Note to the date of payment plus the amounts referred to in clauses (x), (y) and (z) shall collectively be known
as the “Default Amount”) and all other amounts payable hereunder shall immediately become due and payable, all without demand,
presentment or notice, all of which hereby are expressly waived, together with all costs, including, without limitation, legal fees and
expenses, of collection, and the Holder shall be entitled to exercise all other rights and remedies available at law or in equity. 

 

If
the Borrower fails to pay the Default Amount within five (5) business days of written notice that such amount is due and payable, then
the Holder shall have the right at any time, so long as the Borrower remains in default (and so long and to the extent that there are
sufficient authorized shares), to require the Borrower, upon written notice, to immediately issue, in lieu of the Default Amount, the
number of shares of Common Stock of the Borrower equal to the Default Amount divided by the Conversion Price then in effect.

 

    9

     

    

 

Article
IV. MISCELLANEOUS

 

4.1 Failure
or Indulgence Not Waiver. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privileges. All rights and remedies existing hereunder are cumulative to, and not exclusive
of, any rights or remedies otherwise available.

 

4.2 Notices.
All notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and,
unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return receipt
requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by hand delivery,
telegram, facsimile or email, addressed as set forth below or to such other address as such party shall have specified most recently
by written notice. Any notice or other communication required or permitted to be given hereunder shall be deemed effective (a) upon hand
delivery or delivery by facsimile, with accurate confirmation generated by the transmitting facsimile machine, at the address or number
designated below (if delivered on a business day during normal business hours where such notice is to be received), or the first business
day following such delivery (if delivered other than on a business day during normal business hours where such notice is to be received)
or (b) on the second business day following the date of mailing by express courier service, fully prepaid, addressed to such address,
or upon actual receipt of such mailing, whichever shall first occur. The addresses for such communications shall be:

 

If
to the Borrower, to:

 

GZ6G
Technologies Corp.

8925
West Post Road, Suite 102

Las
Vegas, NV 89148

Attn:
William Coleman Smith, Chief Executive Officer

Email: Cole@greenzebra.net

 

If
to the Holder:

 

1800
DIAGONAL LENDING LLC

1800
Diagonal Road, Suite 623

Alexandria,
VA 22314

Attn:
Curt Kramer, President

e-mail:
ckramer@sixthstreetlending.com

 

With
a copy by fax only to (which copy shall not constitute notice):

 

Naidich
Wurman LLP

111
Great Neck Road, Suite 216

Great
Neck, NY 11021

Attn:
Allison Naidich

facsimile:
516-466-3555

e-mail:
allison@nwlaw.com

 

    10

     

    

 

4.3 Amendments.
This Note and any provision hereof may only be amended by an instrument in writing signed by the Borrower and the Holder. The term “Note”
and all reference thereto, as used throughout this instrument, shall mean this instrument (and the other Notes issued pursuant to the
Purchase Agreement) as originally executed, or if later amended or supplemented, then as so amended or supplemented.

 

4.4 Assignability.
This Note shall be binding upon the Borrower and its successors and assigns, and shall inure to be the benefit of the Holder and its
successors and assigns. Each transferee of this Note must be an “accredited investor” (as defined in Rule 501(a) of the Securities
and Exchange Commission). Notwithstanding anything in this Note to the contrary, this Note may be pledged as collateral in connection
with a bona fide margin account or other lending arrangement; and may be assigned by the Holder without the consent of the Borrower.

 

4.5 Cost
of Collection. If default is made in the payment of this Note, the Borrower shall pay the Holder hereof costs of collection, including
reasonable attorneys’ fees.

 

4.6 Governing
Law. This Note shall be governed by and construed in accordance with the laws of the State of Virginia without regard to principles
of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this Note shall
be brought only in the state courts of Virginia or in the federal courts located in the state and city of Alexandria, Virginia. The parties
to this Note hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert
any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The Borrower and Holder waive trial by
jury. The Holder shall be entitled to recover from the Borrower its reasonable attorney’s fees and costs. In the event that any
provision of this Note or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute
or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified
to conform with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect
the validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process
and consents to process being served in any suit, action or proceeding in connection with this Note, any agreement or any other document
delivered in connection with this Note by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence
of delivery) to such party at the address in effect for notices to it under this Note and agrees that such service shall constitute good
and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law.

 

4.7 Purchase
Agreement. By its acceptance of this Note, each party agrees to be bound by the applicable terms of the Purchase Agreement.

 

4.8 Remedies.
The Borrower acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder, by vitiating the
intent and purpose of the transaction contemplated hereby. Accordingly, the Borrower acknowledges that the remedy at law for a breach
of its obligations under this Note will be inadequate and agrees, in the event of a breach or threatened breach by the Borrower of the
provisions of this Note, that the Holder shall be entitled, in addition to all other available remedies at law or in equity, and in addition
to the penalties assessable herein, to an injunction or injunctions restraining, preventing or curing any breach of this Note and to
enforce specifically the terms and provisions thereof, without the necessity of showing economic loss and without any bond or other security
being required.

 

    11

     

    

 

IN
WITNESS WHEREOF, Borrower has caused this Note to be signed in its name by its duly authorized officer this on August 23, 2022

 

GZ6G
Technologies Corp.

 

	By:	 	
	 	William
Coleman Smith

Chief
Executive Officer

	 

 

    12

     

    

EXHIBIT A -- NOTICE OF CONVERSION

 

The
undersigned hereby elects to convert $_________________ principal amount of the Note (defined below) into that number
of shares of Common Stock to be issued pursuant to the conversion of the Note (“Common Stock”) as set forth below,
of GZ6G Technologies Corp., a Nevada corporation (the “Borrower”) according to the conditions of the convertible note of
the Borrower dated as of August 23, 2022 (the “Note”), as of the date written below. No fee will be charged to the Holder
for any conversion, except for transfer taxes, if any.

 

Box
Checked as to applicable instructions:

 

		☐	The
Borrower shall electronically transmit the Common Stock issuable pursuant to this Notice of Conversion to the account of the undersigned
or its nominee with DTC through its Deposit Withdrawal Agent At Custodian (“DWAC Transfer”).

 

Name
of DTC Prime Broker:

Account
Number:

 

		☐	The
undersigned hereby requests that the Borrower issue a certificate or certificates for the number of shares of Common Stock set forth
below (which numbers are based on the Holder’s calculation attached hereto) in the name(s) specified immediately below or, if additional
space is necessary, on an attachment hereto:

  

Date
of conversion: _____________

Applicable
Conversion Price: $____________

Number
of shares of common stock to be issued

pursuant
to conversion of the Notes: ______________

Amount
of Principal Balance due remaining

under
the Note after this conversion: ______________

 

1800
DIAGONAL LENDING LLC

 

By:_____________________________

Name:
Curt Kramer

Title:
President

Date:
__________________

 

    13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]